We help life sciences and healthcare companies strengthen R&D capabilities to accelerate innovation, improve productivity, and deliver successful portfolio and asset strategies.

NDB Holding Group supports clients in designing and executing research programs, optimizing development pipelines, and integrating advanced technologies while navigating regulatory requirements and market dynamics. Our approach emphasizes data-driven decision making, operational excellence, and scalable solutions that maximize the value of R&D investments.

Our R&D Practice works with global and regional organizations across pharmaceuticals, biotech, medtech, and healthcare services. With deep expertise in scientific research, clinical development, and regulatory strategy, we help clients benchmark performance, enhance collaboration, and implement tools and processes to drive innovation.

We advise clients on the full R&D lifecycle, from early discovery and clinical development to portfolio management and commercialization readiness. Many of our consultants have backgrounds in life sciences, engineering, and health technology, providing insights into scientific, operational, and strategic aspects of R&D.

Our areas of expertise include:

• Portfolio strategy and management: Prioritizing projects, optimizing resource allocation, and evaluating potential returns to maximize R&D impact.

• Clinical development optimization: Streamlining clinical trials, improving patient recruitment, and enhancing trial design to reduce timelines and costs.

• Innovation and capability building: Implementing tools, digital solutions, and organizational models that accelerate knowledge sharing and cross-functional collaboration.

• Regulatory and compliance support: Navigating global regulatory requirements and ensuring R&D processes meet quality and safety standards.

• Technology-enabled R&D: Leveraging advanced analytics, AI, and digital platforms to enhance research efficiency, predictive modeling, and decision-making.

Recent example of our work:
We helped a global pharmaceutical company redesign its clinical development process by integrating predictive analytics and advanced trial planning. This improved time-to-market by 18%, reduced clinical trial costs by 12%, and enhanced collaboration across multiple research sites.